Trials / Completed
CompletedNCT01112306
ACT-293987 in Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of ACT-293987 in Patients With Pulmonary Arterial Hypertension
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 709 (actual)
- Sponsor
- Actelion · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Long-term, single-arm, multicenter, open-label extension, Phase 3 study, to evaluate the safety and tolerability of ACT-293987 in patients with PAH who participated in the double-blind study AC-065A302 (GRIPHON)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ACT-293987 | Tablets, twice daily |
Timeline
- Start date
- 2010-07-07
- Primary completion
- 2021-08-26
- Completion
- 2021-08-26
- First posted
- 2010-04-28
- Last updated
- 2025-03-30
- Results posted
- 2022-09-19
Locations
157 sites across 38 countries: United States, Argentina, Australia, Austria, Belarus, Belgium, Canada, Chile, China, Colombia, Czechia, Denmark, France, Germany, Greece, Hungary, India, Ireland, Israel, Malaysia, Mexico, Netherlands, Peru, Poland, Romania, Russia, Serbia, Singapore, Slovakia, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey (Türkiye), Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT01112306. Inclusion in this directory is not an endorsement.